Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20%
Novartis revealed that its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done. The results were published in the New England Journal of Medicine. August 30, 2014